Alibaba Health Information Technology Limited provides earning guidance for the six months ended September 30, 2021. The Group expects to record as compared with the net profit of approximately RMB 279 million for the corresponding period in 2020. The Group's net loss was mainly attributable to the following reasons: (i) the increase in the deployment of the Group's resources to invest in a series of innovative business areas such as the ``Dr. Deer'' APP and health insurance; (ii) the Group's continuous investment in drug supply chain capabilities, including drug storage and logistics, as well as operational service improvements in the Group's pharmaceutical direct sales business, customer experiences in prescription refills and the research and development of the skills for prescription drug regulatory compliance and safety; (iii) the Group's increasing investment in building the brand awareness of Tmall's Pharmaceutical Platform and Alibaba Health Pharmacy; (iv) decrease in operating margin of the Group's direct sales business as the Group increased its market share of online B2C drug sales, accelerated business deployment of prescription drug sales business and increased the deployment of corresponding market resources; partially offset by (v) the increase in unrealised gain on changes in fair values of investment.